Article Details
Retrieved on: 2024-12-21 15:07:32
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses FDA approval of Eli Lilly's drug Zepbound for treating obstructive sleep apnea, particularly in obese adults. It demonstrates significant weight loss and breathing disruption reduction, highlighting intersections with sleep disorders and diabetes management.
Article found on: www.aol.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here